iRobot receives FDA approval
iRobot Corp (IRBT), a leader in delivering robotic solutions, announced today that RP-VITA Remote Presence Robot has received 510(k) clearance by the US Food and Drug Administration (FDA) for use in hospitals. iRobot’s RP-VITA is the first autonomous navigation remote presence robot to receive FDA clearance.
Since the announcement was made, IRBT shares increased from $2.21, or 10.5%, to $23.32.
RP-VITA was developed by iRobot and InTouch Health and combines the latest in autonomous navigation and mobility technologies as well as state-of-the-art telemedicine and electronic health record integration.
In a nutshell, the robot will allow doctors to visit hospital patients remotely. They will be able to view and communicate with the patient via a high-tech iPad application.
According to iRobot, the FDA clearance states RP-VITA ‘can be used for active patient monitoring in pre-operative, peri-operative and post-surgical settings, including cardiovascular, neurological, prenatal, psychological and critical care assessments and examinations.’
This is the first robot to be cleared for everyday use in a hospital setting, sparking a new development in the way we access and communicate with medical professionals in the future.
How do you feel about iRobot’s latest clearance? Join the discussion on Twitter @HealthCareG
- Prostate cancer drug fast-tracked for FDA approvalMedical Devices & Pharma
- 23andMe granted FDA Authorisation for direct-to-consumer pharmacogenetic reportsMedical Devices & Pharma
- IDx gains $33mn in Series A fundingTechnology & AI
- AstraZeneca acquires FDA breakthrough therapy label for asthma drugMedical Devices & Pharma
